[go: up one dir, main page]

CA3204457A1 - Mdma dans le traitement d'un trouble de consommation d'alcool - Google Patents

Mdma dans le traitement d'un trouble de consommation d'alcool Download PDF

Info

Publication number
CA3204457A1
CA3204457A1 CA3204457A CA3204457A CA3204457A1 CA 3204457 A1 CA3204457 A1 CA 3204457A1 CA 3204457 A CA3204457 A CA 3204457A CA 3204457 A CA3204457 A CA 3204457A CA 3204457 A1 CA3204457 A1 CA 3204457A1
Authority
CA
Canada
Prior art keywords
mdma
subject
psychotherapy
alcohol
assisted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204457A
Other languages
English (en)
Inventor
Ben SESSA
Laurie HIGBED
David Nutt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Awakn Ls Europe Holdings Ltd
Original Assignee
Awakn Ls Europe Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Awakn Ls Europe Holdings Ltd filed Critical Awakn Ls Europe Holdings Ltd
Publication of CA3204457A1 publication Critical patent/CA3204457A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention divulgue des compositions de MDMA et des procédés d'utilisation de celles-ci dans la psychothérapie assistée par MDMA pour le traitement de patients atteints d'un trouble de consommation d'alcool (AUD) comprenant un trouble de consommation d'alcool dépendant physiquement («?consommation dépendante?» ou «?dépendance à l'alcool?») et un trouble de consommation d'alcool non dépendant physiquement («?consommation nocive?»).
CA3204457A 2021-01-06 2022-01-06 Mdma dans le traitement d'un trouble de consommation d'alcool Pending CA3204457A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163134582P 2021-01-06 2021-01-06
US63/134,582 2021-01-06
US202163137615P 2021-01-14 2021-01-14
US63/137,615 2021-01-14
PCT/US2022/011511 WO2022150525A1 (fr) 2021-01-06 2022-01-06 Mdma dans le traitement d'un trouble de consommation d'alcool

Publications (1)

Publication Number Publication Date
CA3204457A1 true CA3204457A1 (fr) 2022-07-14

Family

ID=80050571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3204457A Pending CA3204457A1 (fr) 2021-01-06 2022-01-06 Mdma dans le traitement d'un trouble de consommation d'alcool

Country Status (2)

Country Link
CA (1) CA3204457A1 (fr)
WO (1) WO2022150525A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022256720A2 (fr) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Compositions entactogènes énantiomères et leurs méthodes d'utilisation
IL310937A (en) * 2021-08-20 2024-04-01 Pharmala Biotech Inc Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
US11993577B2 (en) 2021-09-01 2024-05-28 Empathbio, Inc. Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomers
EP4408832A1 (fr) 2021-10-01 2024-08-07 Empathibio, Inc. Nouveaux promédicaments de mdma, mda et leurs dérivés
EP4412608A1 (fr) * 2021-10-07 2024-08-14 Clearmind Medicine Inc. 5-mapb ou 6-apb pour une utilisation dans la psychothérapie assistée par médicament
EP4457222A2 (fr) 2021-12-28 2024-11-06 EmpathBio, Inc. Promédicaments libérant de l'oxyde nitrique de mda et mdma
CN119013009A (zh) * 2022-01-07 2024-11-22 巴塞尔大学医院 用于辅助心理治疗的r-mdma和s-mdma
EP4583862A1 (fr) * 2022-09-09 2025-07-16 atai Life Sciences AG Utilisation de mdma pour le traitement de troubles liés au stress
WO2024064825A1 (fr) * 2022-09-21 2024-03-28 Axsome Therapeutics, Inc. Composés et combinaisons de ceux-ci pour le traitement d'états neurologiques et psychiatriques
WO2024102458A1 (fr) * 2022-11-11 2024-05-16 Gilgamesh Pharmaceuticals, Inc. Méthodes d'utilisation de trazodone pour inverser les effets d'agonistes du récepteur 5-ht2a
WO2024123706A1 (fr) * 2022-12-05 2024-06-13 Lykos Therapeutics, Inc. Compositions comprenant de la mdma et leurs méthodes d'utilisation
WO2024178082A2 (fr) * 2023-02-22 2024-08-29 Freedom Biosciences, Inc. Composition de modulateur des récepteurs opioïdes et mdma pour son utilisation
WO2024182074A1 (fr) * 2023-02-28 2024-09-06 Mind Medicine, Inc. R-mdma pour le traitement de la douleur
WO2024196772A2 (fr) * 2023-03-20 2024-09-26 Mind Medicine, Inc. Énantiomères de mdma

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279194C (fr)
DE274350C (fr) 1912-12-24 1914-05-16 Merck E
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3684446D1 (de) 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
JP2527107B2 (ja) 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
DE69231313T2 (de) 1991-11-22 2001-03-15 Procter & Gamble Pharmaceuticals, Inc. Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
ATE223704T1 (de) 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
WO2019026019A1 (fr) 2017-08-03 2019-02-07 Therapeutic Adjuncts Inc. Utilisation de 3-méthylmethcathinone

Also Published As

Publication number Publication date
WO2022150525A1 (fr) 2022-07-14
WO2022150525A9 (fr) 2023-04-20

Similar Documents

Publication Publication Date Title
CA3204457A1 (fr) Mdma dans le traitement d'un trouble de consommation d'alcool
US20220169668A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CA3072780C (fr) Utilisation de 3-methylmethcathinone dans une intervention psychotherapeutique
Shahrokh et al. The language of mental health: A glossary of psychiatric terms
EA038339B1 (ru) Способы лечения аутизма
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
CA3240774A1 (fr) Psilocybine et inhibiteur de la recapture de la serotonine complementaire destines a etre utilises dans le traitement de la depression resistante au traitement
WO2022238507A1 (fr) Composés et compositions thérapeutiques à base d'aminoindane
US20240197652A1 (en) Ketamine in the treatment of behavioral addictions
US20240122895A1 (en) Entactogen-assisted therapy for alcohol use disorder and addiction-related conditions and comorbidities
Baggott et al. 3, 4-Methylenedioxymethamphetamine (MDMA): A review of the English-language scientific and medical literature
US20250186458A1 (en) Methods for the treatment of mild cognitive impairment
KR20250011101A (ko) 엔탁토겐성 마음상태를 설계 및 생성하기 위한 치료적 조합, 조성물, 및 방법
WO2025145241A1 (fr) Traitement des troubles de l'interaction intestin-cerveau
CN118488843A (zh) 用赛洛西宾治疗难治性抑郁症
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
HK40068314A (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
HK40068334A (en) Treatment of depression and other various disorders with psilocybin
Saklayen Effects of propranolol on cognition and eye contact in autism spectrum disorder (ASD)